Back to resultsAdiponectin and Insulin Resistance in Diabetic Nephropathy
Primary Purpose
Diabetic Nephropathy
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Losartan
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Nephropathy focused on measuring Type 2 Diabetes, Diabetic Nephropathy, Glucose Metabolism, Angiotensin II Type 1 Receptor Blockers
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetic nephropathy
- CKD at stage 1~4
Exclusion Criteria:
- Type 1 diabetes or nondiabetic renal disease
- An elevated plasma K level.
Sites / Locations
- Shanghai No.3 people's hospital
Outcomes
Primary Outcome Measures
GFR, HbA1c and the adiponectin concentration
Secondary Outcome Measures
Full Information
NCT ID
NCT00774904
First Posted
October 16, 2008
Last Updated
October 17, 2008
Sponsor
Health Science Center of Xi'an Jiaotong University
Collaborators
Shanghai Jiao Tong University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT00774904
Brief Title
Adiponectin and Insulin Resistance in Diabetic Nephropathy
Official Title
Adiponectin is Positively Associated With Insulin Resistance in Subjects With Type 2 Diabetic Nephropathy and Effects by Angiotensin Type 1 Receptor Blocker Losartan
Study Type
Interventional
2. Study Status
Record Verification Date
October 2008
Overall Recruitment Status
Completed
Study Start Date
April 2007 (undefined)
Primary Completion Date
October 2007 (Actual)
Study Completion Date
November 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Health Science Center of Xi'an Jiaotong University
Collaborators
Shanghai Jiao Tong University School of Medicine
4. Oversight
5. Study Description
Brief Summary
Plasma adiponectin concentration is inversely associated with renal function. There is little literature on adiponectin levels and regulation by antihypertensive medication with an angiotensin II-receptor blocker (ARB), especially in subjects with type 2 diabetes in different stage of chronic kidney disease (CKD).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Nephropathy
Keywords
Type 2 Diabetes, Diabetic Nephropathy, Glucose Metabolism, Angiotensin II Type 1 Receptor Blockers
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Losartan
Intervention Description
Angiotensin II Type 1 Receptor Blockers
Primary Outcome Measure Information:
Title
GFR, HbA1c and the adiponectin concentration
Time Frame
6 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetic nephropathy
CKD at stage 1~4
Exclusion Criteria:
Type 1 diabetes or nondiabetic renal disease
An elevated plasma K level.
Facility Information:
Facility Name
Shanghai No.3 people's hospital
City
Shanghai
ZIP/Postal Code
201900
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
25502581
Citation
Pan Y, Qiao QY, Pan LH, Zhou DC, Hu C, Gu HF, Fu SK, Liu XL, Jin HM. Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Exp Clin Endocrinol Diabetes. 2015 Mar;123(3):170-7. doi: 10.1055/s-0034-1395658. Epub 2014 Dec 11.
Results Reference
derived
Learn more about this trial
Adiponectin and Insulin Resistance in Diabetic Nephropathy
We'll reach out to this number within 24 hrs